Benzinga··Vandana SinghAbbott's Strong AFib Data Bolsters Cardiac Device Pipeline, Signals Market Growth
Abbott reports strong clinical trial data for AFib and cardiac devices, with 87% arrhythmia-free rates and 98.3% safety in FlexPulse study, supporting future revenue growth.
ABTclinical trialsmedical devices